Share this post on:

FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Life Sciences Venture Capital Monitor – Europe 01/2022”.

The Monitor is a monthly published overview of venture capital trends in the European Life Sciences sector.

As of the end of January 2022 we identify the following current VC trends in Europe:

  • The current funding for life sciences amounts to EUR 957m and is thus about EUR 400m below the previous year’s level
  • The top 5 deals are each above EUR 50m, the largest deal is above EUR 100m and took place in Germany (Patient21)
  • Target Global (Germany) ranks first among the top 5 investors (by deal volume), followed by Piton Capital (UK) and Eight Roads (USA)
  • 35% of total investment volume was placed in the biotech sector (+7% points month-on-month)
  • Infectious diseases is the indication with the highest investment activity in the biotech sector

To access the full report, please click here.

By Dr. Mathias Schott and Sebastian Sommer

Source link

Share this post on:

Leave a Comment

Your email address will not be published. Required fields are marked *